Recruiting

Microarrays

Sponsor:

University of Alberta

Code:

NCT03193151

Conditions

Liver Dysfunction

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

liver biopsy

Study Details

Brief summary:

INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.

Conditions

Liver Dysfunction

Study ID

NCT03193151

Start date

Dec 19, 2017

Status verified date

Jun, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • biopsy for clinical indications

Exclusion Criteria:

  • no consent, pregnant women

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Interventions

liver biopsy

5 mm fragment of liver transplant biopsy taken for clinical indication

Primary outcome measure

  • Assign molecular scores (probability) of T cell mediated rejection, antibody mediated rejection in liver transplant biopsies, in a reference set of 100 biopsies [ Time Frame: two years ]

Central Contacts and Locations

Central contacts

Konrad S Famulski, PhD

1 780 492 1725konrad@ualberta.ca

Robert Polakowski, PhD

1 780 492 5091polakows@ualberta.ca

Locations

Henry Ford Transplant Institute

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Dilip Moonka, MD

DMOONKA1@hfhs.org

Sierra Foley

SFoley3@hfhs.org

Principal Investigator:

Marwan Abouljoud, MD

More Information

Sponsor

University of Alberta

Last update posted

Jun 4, 2026

Last verified

Jun, 2026

Keywords

  • Liver transplant
  • global gene expression
  • molecular diagnostics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Alberta on 2026-06-04.